HC Wainwright Issues Negative Estimate for Geron Earnings

Geron Co. (NASDAQ:GERN) – HC Wainwright cut their Q3 2025 earnings per share estimates for shares of Geron in a report issued on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter, down from their previous forecast of ($0.02). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.11) EPS and FY2027 earnings at ($0.04) EPS.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. The business had revenue of $39.60 million for the quarter, compared to analyst estimates of $49.88 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company’s quarterly revenue was up 12927.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.07) EPS.

Several other brokerages also recently issued reports on GERN. Barclays reiterated an “overweight” rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a report on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price target on shares of Geron in a report on Wednesday, March 12th. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and lowered their price target for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Stifel Nicolaus lowered their price target on Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Finally, Scotiabank downgraded Geron from a “sector outperform” rating to a “sector perform” rating and lowered their price target for the company from $4.00 to $1.50 in a report on Thursday. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.06.

Geron Trading Down 6.0%

Shares of Geron stock opened at $1.19 on Monday. Geron has a fifty-two week low of $1.17 and a fifty-two week high of $5.34. The firm has a market cap of $754.75 million, a PE ratio of -3.70 and a beta of 0.76. The business’s fifty day moving average is $1.49 and its two-hundred day moving average is $2.72. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04.

Hedge Funds Weigh In On Geron

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Geron by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 34,146,851 shares of the biopharmaceutical company’s stock valued at $54,293,000 after buying an additional 608,029 shares during the last quarter. Janus Henderson Group PLC boosted its position in Geron by 20.0% in the 4th quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock valued at $95,769,000 after buying an additional 4,516,615 shares during the last quarter. Wellington Management Group LLP boosted its position in Geron by 6.7% in the 4th quarter. Wellington Management Group LLP now owns 13,510,114 shares of the biopharmaceutical company’s stock valued at $47,826,000 after buying an additional 847,710 shares during the last quarter. Geode Capital Management LLC boosted its position in Geron by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 13,141,514 shares of the biopharmaceutical company’s stock valued at $46,531,000 after buying an additional 73,515 shares during the last quarter. Finally, Woodline Partners LP boosted its position in Geron by 64.6% in the 4th quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company’s stock valued at $41,019,000 after buying an additional 4,549,031 shares during the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.